MX2018003008A - Heteroarilos sustituidos con pirazolilo y su uso como medicamentos. - Google Patents

Heteroarilos sustituidos con pirazolilo y su uso como medicamentos.

Info

Publication number
MX2018003008A
MX2018003008A MX2018003008A MX2018003008A MX2018003008A MX 2018003008 A MX2018003008 A MX 2018003008A MX 2018003008 A MX2018003008 A MX 2018003008A MX 2018003008 A MX2018003008 A MX 2018003008A MX 2018003008 A MX2018003008 A MX 2018003008A
Authority
MX
Mexico
Prior art keywords
pyrazolyl
medicaments
substituted heteroaryls
formula
lupus
Prior art date
Application number
MX2018003008A
Other languages
English (en)
Inventor
Hoffmann Matthias
Dahmann Georg
Mccarthy Clive
Gnamm Christian
Scott John
Fandrick Daniel
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of MX2018003008A publication Critical patent/MX2018003008A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Virology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Otolaryngology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La invención se refiere a nuevos heteroarilos sustituidos de la fórmula 1 (ver Fórmula). o de la fórmula 1´ (ver Fórmula). en donde A es N o CH, en donde R2 se selecciona del grupo que consiste en -alquilo de C1-3, -haloalquilo de C1-3, F, Br, C1, en donde y se selecciona de -O- o -CH2-, y en donde R3 se define como en la reivindicación 1 y sus sales farmacéuticamente aceptables, y el uso de estos compuestos antes mencionados para el tratamiento de enfermedades tales como asma, EPOC, rinitis alérgica, dermatitis alérgica, lupus eritematoso, lupus nefrítico y artritis reumatoidea.
MX2018003008A 2015-09-11 2016-09-02 Heteroarilos sustituidos con pirazolilo y su uso como medicamentos. MX2018003008A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562217269P 2015-09-11 2015-09-11
PCT/EP2016/070729 WO2017042100A1 (en) 2015-09-11 2016-09-02 Pyrazolyl-substituted heteroaryls and their use as medicaments

Publications (1)

Publication Number Publication Date
MX2018003008A true MX2018003008A (es) 2018-04-11

Family

ID=56852283

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018003008A MX2018003008A (es) 2015-09-11 2016-09-02 Heteroarilos sustituidos con pirazolilo y su uso como medicamentos.

Country Status (19)

Country Link
US (2) US9845314B2 (es)
EP (1) EP3347353B1 (es)
JP (1) JP6868011B2 (es)
KR (1) KR20180051624A (es)
CN (1) CN108026080B (es)
AR (1) AR105991A1 (es)
AU (1) AU2016320297B2 (es)
CA (1) CA2998250A1 (es)
CL (1) CL2018000400A1 (es)
DK (1) DK3347353T3 (es)
EA (1) EA033978B1 (es)
ES (1) ES2745284T3 (es)
HU (1) HUE046920T2 (es)
IL (1) IL257392B (es)
MX (1) MX2018003008A (es)
PH (1) PH12018500533A1 (es)
PL (1) PL3347353T3 (es)
TW (1) TW201720799A (es)
WO (1) WO2017042100A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20160115953A (ko) 2014-01-31 2016-10-06 다나-파버 캔서 인스티튜트 인크. 디아미노피리미딘 벤젠술폰 유도체 및 그의 용도
WO2015117087A1 (en) 2014-01-31 2015-08-06 Dana-Farber Cancer Institute, Inc. Uses of diazepane derivatives
LT3119772T (lt) 2014-03-19 2019-08-26 Boehringer Ingelheim International Gmbh Heteroarilo sik inhibitoriai
UA123946C2 (uk) 2015-09-11 2021-06-30 Дана-Фарбер Кенсер Інстітьют, Інк. Ацетамідтієнотриазолодіазепіни й шляхи їх застосування
EA033978B1 (ru) 2015-09-11 2019-12-16 Бёрингер Ингельхайм Интернациональ Гмбх Пиразолилзамещенные гетероарилы и их применение в качестве лекарственных средств
RU2750164C2 (ru) 2015-09-11 2021-06-22 Дана-Фарбер Кэнсер Инститьют, Инк. Цианотиенотриазолодиазепины и пути их применения
WO2017091673A2 (en) 2015-11-25 2017-06-01 Dana-Farber Cancer Institute, Inc. Bivalent bromodomain inhibtors and uses thereof
TW201927769A (zh) * 2017-12-18 2019-07-16 德商歌林達有限公司 經取代之吡咯啶醯胺ｉｉ
US11633399B2 (en) 2018-12-25 2023-04-25 Sol-Gel Technologies Ltd. Treatment of skin disorders with compositions comprising an EGFR inhibitor
WO2022090481A1 (en) 2020-11-02 2022-05-05 Boehringer Ingelheim International Gmbh Substituted 1h-pyrazolo[4,3-c]pyridines and derivatives as egfr inhibitors
CN115197115A (zh) * 2022-08-25 2022-10-18 成都金博汇康医药科技有限公司 一种手性5-氧代吡咯烷-3-甲酸的制备方法与应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001302667A (ja) 2000-04-28 2001-10-31 Bayer Ag イミダゾピリミジン誘導体およびトリアゾロピリミジン誘導体
US7432266B2 (en) * 2004-10-15 2008-10-07 Memory Pharmaceuticals Corporation Phosphodiesterase 4 inhibitors
JP5055263B2 (ja) * 2005-03-30 2012-10-24 ダエウン ファーマシューティカル カンパニー リミテッド 抗真菌性トリアゾール誘導体
US20110201608A1 (en) 2008-08-05 2011-08-18 Boehringer Ingelheim International Gmbh Substituted naphthyridines and use thereof as medicines
JP5754568B2 (ja) 2008-08-05 2015-07-29 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ４−ジメチルアミノ−フェニルで置換されているナフチリジン、及び医薬としてのその使用
TWI453207B (zh) 2008-09-08 2014-09-21 Signal Pharm Llc 胺基三唑并吡啶，其組合物及使用其之治療方法
ES2744541T3 (es) * 2008-12-08 2020-02-25 Gilead Connecticut Inc Inhibidores de imidazopirazina Syk
CA2786245A1 (en) 2010-01-29 2011-08-04 Boehringer Ingelheim International Gmbh Substituted naphthyridines and their use as syk kinase inhibitors
US20140005188A1 (en) 2011-03-11 2014-01-02 Glaxo Group Limited Pyrido[3,4-b]pyrazine derivatives as syk inhibitors
ES2588680T3 (es) 2011-03-28 2016-11-04 F. Hoffmann-La Roche Ag Compuestos de tiazolopirimidina
MX336224B (es) 2011-07-26 2016-01-12 Boehringer Ingelheim Int Quinolinas sustituidas y su uso como medicamentos.
WO2013047813A1 (ja) * 2011-09-30 2013-04-04 大鵬薬品工業株式会社 １，２，４－トリアジン－６－カルボキサミド誘導体
EP2858994A1 (en) 2012-06-07 2015-04-15 F. Hoffmann-La Roche AG Pyrazolopyrimidone and pyrazolopyridone inhibitors of tankyrase
WO2014100113A2 (en) 2012-12-18 2014-06-26 Hulow, Llc Syk kinase inhibitors as treatment for malaria
EA031601B1 (ru) * 2013-07-31 2019-01-31 Джилид Сайэнс, Инк. Ингибиторы syk
SG11201605408RA (en) * 2014-01-10 2016-07-28 Aurigene Discovery Tech Ltd Indazole compounds as irak4 inhibitors
LT3119772T (lt) 2014-03-19 2019-08-26 Boehringer Ingelheim International Gmbh Heteroarilo sik inhibitoriai
TW201617074A (zh) * 2014-07-14 2016-05-16 吉李德科學股份有限公司 Ｓｙｋ（脾酪胺酸激酶）抑制劑
EA033978B1 (ru) 2015-09-11 2019-12-16 Бёрингер Ингельхайм Интернациональ Гмбх Пиразолилзамещенные гетероарилы и их применение в качестве лекарственных средств

Also Published As

Publication number Publication date
DK3347353T3 (da) 2019-10-21
AU2016320297A1 (en) 2018-02-08
EP3347353B1 (en) 2019-07-17
CL2018000400A1 (es) 2018-07-13
US10155751B2 (en) 2018-12-18
AU2016320297B2 (en) 2020-08-27
PL3347353T3 (pl) 2020-01-31
US20170073333A1 (en) 2017-03-16
US20180148433A1 (en) 2018-05-31
JP6868011B2 (ja) 2021-05-12
TW201720799A (zh) 2017-06-16
CA2998250A1 (en) 2017-03-16
IL257392B (en) 2020-05-31
KR20180051624A (ko) 2018-05-16
ES2745284T3 (es) 2020-02-28
AR105991A1 (es) 2017-11-29
EA033978B1 (ru) 2019-12-16
EA201890695A1 (ru) 2018-09-28
CN108026080A (zh) 2018-05-11
WO2017042100A1 (en) 2017-03-16
HUE046920T2 (hu) 2020-03-30
IL257392A (en) 2018-04-30
EP3347353A1 (en) 2018-07-18
JP2018529679A (ja) 2018-10-11
CN108026080B (zh) 2021-06-11
US9845314B2 (en) 2017-12-19
PH12018500533A1 (en) 2018-09-10

Similar Documents

Publication Publication Date Title
PH12018500533A1 (en) Pyrazolyl-substituted heteroaryls and their use as medicaments
PH12016502081A1 (en) Compounds for treating spinal muscular atrophy
PH12016502382A1 (en) Substituted indazole compounds as irak4 inhibitors
MY185837A (en) Heteroaryl syk inhibitors
GEP20217248B (en) 2,4,5-trisubstituted 1,2,4-triazolones useful as inhibitors of dhodh
MX2018005890A (es) Composiciones para tratar atrofia muscular espinal.
MX2022012317A (es) Oxisteroles y metodos de uso de los mismos.
GEP20207105B (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors
PH12018500061A1 (en) Oxysterols and methods of use thereof
PH12014502341A1 (en) Amino-indolyl-substituted imidazolyl-pyrimidines and their use as medicaments
EA201791802A1 (ru) СШИТЫЕ ДИГИДРО-4H-ПИРАЗОЛО[5,1-c][1,4]ОКСАЗИНИЛОВЫЕ СОЕДИНЕНИЯ И АНАЛОГИ ДЛЯ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ ЦНС
MX2016015248A (es) Compuestos imidazo[1,2-a]pirazin-1-il-benzamida para tratar atrofia muscular espinal.
MX2018005041A (es) Compuestos para tratar la esclerosis lateral amiotrofica.
GEP20196949B (en) 2-amino-6-(difluoromethyl)-5, 5-difluoro-6-phenyl-3, 4, 5, 6-tetra- hydropyridines as bace1 inhibitors
PH12016501977A1 (en) 2-AMINO-6-METHYL-4,4a,5,6-TETRAHYDROPYRANO[3,4-d][1,3]THIAZIN-8a(8H)-YL-1,3-THIAZOL-4-YL AMIDES
PH12016502394A1 (en) 1, 3, 4-thiadiazole compounds and their use in treating cancer
TW201613890A (en) Pyridine derivatives as muscarinic M1 receptor positive allosteric modulators
SA519401322B1 (ar) مركبات أريل كربوكساميد غير متجانسة كمثطبات لكيناز بروتين سيرين/ ثريونين متداخل مع المستقبل 2
PH12015501962A1 (en) Novel inhibitor compounds of phosphodiesterase type 10a
PH12016500197A1 (en) Novel biphenyl derivative and method for preparing same
PH12016502480A1 (en) Compounds, pharmaceutical composition and their use in treating neurodegenerative diseases
PH12017501134A1 (en) Fumagillol derivatives
MX2017008497A (es) Nuevos compuestos heterocíclicos y su uso tanto en medicina como en cosmética.
IN2013MU03838A (es)

Legal Events

Date Code Title Description
FG Grant or registration